Ocata Therapeutics, Inc.: 10-K filed 2014-04-01

Name: Ocata Therapeutics, Inc.: 10-K filed 2014-04-01
Creator: Ocata Therapeutics, Inc.

What Ocata Therapeutics, Inc. reported in its annual report filed 2014-04-01 (fiscal FY 2013): 35 published measures, 91 facts as tagged in accession 0001019687-14-001176.

This filing

Form: 10-K (annual report)
Filed: 2014-04-01
Fiscal period: fiscal FY 2013
Accession: 0001019687-14-001176 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Ocata Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-12-31	3,907,919	USD
At 2012-12-31	8,496,542	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2013-12-31	26,441,529	USD
At 2012-12-31	30,042,223	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2013-12-31	-22,533,610	USD
At 2012-12-31	-23,144,214	USD
At 2011-12-31	-48,556,062	USD
At 2010-12-31	-46,123,844	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-12-31	1,743,485	USD
At 2012-12-31	7,241,852	USD
At 2011-12-31	13,103,007	USD
At 2010-12-31	15,889,409	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	-31,022,248	USD	365
2012-01-01 to 2012-12-31	-34,584,115	USD	366
2011-01-01 to 2011-12-31	-55,192,803	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	671,827	USD	365
2012-01-01 to 2012-12-31	96,260	USD	366
2011-01-01 to 2011-12-31	36,830	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2013-12-31	-313,844,357	USD
At 2012-12-31	-282,847,861	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	2,086,619,741	shares	366
2011-01-01 to 2011-12-31	1,582,095,095	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	2,086,619,741	shares	366
2011-01-01 to 2011-12-31	1,582,095,095	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	-0.02	USD/shares	366
2011-01-01 to 2011-12-31	-0.03	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2012-01-01 to 2012-12-31	-0.02	USD/shares	366
2011-01-01 to 2011-12-31	-0.03	USD/shares	365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2013-01-01 to 2013-12-31	USD	365
2012-01-01 to 2012-12-31	USD	366
2011-01-01 to 2011-12-31	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2013-12-31	753,576	USD
At 2012-12-31	175,256	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	3,880,058	USD	365
2012-01-01 to 2012-12-31	7,795,885	USD	366
2011-01-01 to 2011-12-31	67,286	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	-29,707,907	USD	365
2012-01-01 to 2012-12-31	-25,242,751	USD	366
2011-01-01 to 2011-12-31	-17,321,143	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-12-31	2,911,859	USD
At 2012-12-31	7,552,756	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	1,437,584	USD	365
2012-01-01 to 2012-12-31	1,104,602	USD	366
2011-01-01 to 2011-12-31	1,510,693	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2013-12-31	22,916,789	USD
At 2012-12-31	23,490,235	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2013-12-31	2,285,331	USD
At 2012-12-31	2,956,743	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	29,850,456	USD	365
2012-01-01 to 2012-12-31	25,591,802	USD	366
2011-01-01 to 2011-12-31	17,483,612	USD	365

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	142,549	USD	365
2012-01-01 to 2012-12-31	349,051	USD	366
2011-01-01 to 2011-12-31	162,469	USD	365

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	82,436	USD	365
2012-01-01 to 2012-12-31	117,436	USD	366
2011-01-01 to 2011-12-31	343,950	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	11,564,768	USD	365
2012-01-01 to 2012-12-31	14,158,936	USD	366
2011-01-01 to 2011-12-31	9,753,759	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-12-31	2,640,264,975	shares
At 2012-12-31	2,232,720,779	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-12-31	322,683,874	USD
At 2012-12-31	289,093,619	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2013-12-31	1,735,259	USD
At 2012-12-31	1,116,982	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2013-12-31	981,683	USD
At 2012-12-31	941,726	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2013-12-31	3,545,713	USD
At 2012-12-31	3,210,908	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	12,057,067	USD	365
2012-01-01 to 2012-12-31	11,432,866	USD	366
2011-01-01 to 2011-12-31	7,435,709	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	93,507	USD	365
2012-01-01 to 2012-12-31	58,637	USD	366
2011-01-01 to 2011-12-31	67,161	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	-1,314,341	USD	365
2012-01-01 to 2012-12-31	-9,341,364	USD	366
2011-01-01 to 2011-12-31	-37,871,660	USD	365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	7,968,310	USD	365
2012-01-01 to 2012-12-31	2,021,705	USD	366
2011-01-01 to 2011-12-31	7,878,246	USD	365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	389,133	USD	365
2012-01-01 to 2012-12-31	0	USD	366
2011-01-01 to 2011-12-31	0	USD	365

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Unit	Days
2013-01-01 to 2013-12-31	USD	365
2012-01-01 to 2012-12-31	USD	366
2011-01-01 to 2011-12-31	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	17,777,604	USD	365
2012-01-01 to 2012-12-31	2,941,102	USD	366
2011-01-01 to 2011-12-31	0	USD	365

Inspect the source

Entity: Ocata Therapeutics, Inc. / CIK 0001140098
Captured: 2026-09-22 19:40 UTC
SEC response SHA-256: 35ed5f9b7b65d6962e417af6d880d4a32b17c4db50d76618066bbdf10dcb4c40

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001140098.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))